West Family Investments Inc. Invests $295,000 in Koninklijke Philips N.V. $PHG

West Family Investments Inc. bought a new stake in Koninklijke Philips N.V. (NYSE:PHG) in the 2nd quarter, Holdings Channel.com reports. The fund bought 12,282 shares of the technology company’s stock, valued at approximately $295,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PHG. Dimensional Fund Advisors LP increased its stake in Koninklijke Philips by 2.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock worth $111,662,000 after buying an additional 106,044 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Koninklijke Philips by 15.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 189,720 shares of the technology company’s stock valued at $4,549,000 after buying an additional 24,931 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Koninklijke Philips by 18.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 72,276 shares of the technology company’s stock worth $1,836,000 after acquiring an additional 11,018 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Koninklijke Philips by 2.5% in the second quarter. Envestnet Asset Management Inc. now owns 1,351,015 shares of the technology company’s stock worth $32,397,000 after acquiring an additional 32,663 shares in the last quarter. Finally, Investment Management Associates Inc. ADV purchased a new stake in shares of Koninklijke Philips during the second quarter worth $12,122,000. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on PHG. Weiss Ratings reiterated a “hold (c-)” rating on shares of Koninklijke Philips in a report on Tuesday, November 25th. Wall Street Zen upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Koninklijke Philips currently has a consensus rating of “Buy”.

Koninklijke Philips Stock Performance

Shares of PHG stock opened at $28.16 on Monday. The company has a market cap of $27.12 billion, a P/E ratio of 140.81, a PEG ratio of 0.76 and a beta of 0.79. The firm has a fifty day moving average price of $27.90 and a 200 day moving average price of $26.24. The company has a current ratio of 1.32, a quick ratio of 0.86 and a debt-to-equity ratio of 0.68. Koninklijke Philips N.V. has a 12 month low of $21.48 and a 12 month high of $29.54.

Koninklijke Philips (NYSE:PHG) last announced its quarterly earnings results on Tuesday, November 4th. The technology company reported $0.37 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.37. The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $4.30 billion. Koninklijke Philips had a return on equity of 12.14% and a net margin of 1.07%. Sell-side analysts predict that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.